Advertisement


Joseph A. Sparano, MD, on Early-Stage Breast Cancer: Findings on the Tumor Microenvironment

2016 San Antonio Breast Cancer Symposium

Advertisement

Joseph A. Sparano, MD, of the Montefiore Medical Center, discusses the tumor microenvironment of metastasis score and its association with early distant recurrence in HR-positive, HER2-negative early-stage breast cancer (Abstract S4-04).

To view a short film on capturing imaging inside breast cancer tumors, go to: https://www.youtube.com/watch?v=q_JDp-VePAs



Related Videos

Symptom Management
Breast Cancer

Jame Abraham, MD, on Hair Loss: SCALP Trial Results

Jame Abraham, MD, of the Cleveland Clinic, discusses findings of the Scalp Cooling Alopecia Prevention trial for patients with early-stage breast cancer (Abstract S5-02).

Breast Cancer

Jame Abraham, MD, on ER-Positive Breast Cancer: Expert Perspective on Initial Results of NRG Oncology/NSABP B-42

Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).

Breast Cancer
Symptom Management

Patricia A. Ganz, MD: Aromatase Inhibitors Data Review

Patricia A. Ganz, MD, of the UCLA Jonsson Comprehensive Cancer Center, summarizes two studies on using duloxetine for aromatase inhibitor–associated musculoskeletal symptoms, and aromatase inhibitors’ effect on endothelial function and heart disease (Abstracts S5-06 and S5-07).

Breast Cancer

Rowan T. Chlebowski, MD, PhD, on Diet and Breast Cancer: Trial Results

Rowan T. Chlebowski, MD, PhD, of the David Geffen School of Medicine at UCLA, discusses findings from the Women’s Health Initiative Dietary Modification study on low-fat diet and breast cancer overall survival (Abstract S5-04).

Breast Cancer

Sara A. Hurvitz, MD, on HR-Positive, HER2-Negative Breast Cancer: Results of the neoMONARCH Trial

Sara A. Hurvitz, MD, of the UCLA Jonsson Comprehensive Cancer Center, discusses findings on the biological effects of abemaciclib in a neoadjuvant study for postmenopausal patients (Abstract S4-06).

Advertisement

Advertisement




Advertisement